NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Cabot Oil & Gas Corporation ("Cabot Oil" or the "Company") (NYSE:COG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cabot Oil and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 15, 2020, following a grand jury investigation, the Pennsylvania attorney general's office charged Cabot Oil with 15 criminal counts arising from its failure to fix faulty gas wells, thereby polluting Pennsylvania's water supplies through stray gas migration.

On this news, Cabot Oil's stock price fell $0.67 per share, or 3.34%, to close at $19.40 per share on June 15, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 594635

NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Chembio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

In April 2020, Chembio's Dual Path Platform ("DPP") COVID-19 antibody test was among the first such tests to be granted Emergency Use Authorization ("EUA") by the U.S. Food and Drug Administration ("FDA"). Then, on June 17, 2020, pre-market, news outlets reported that the FDA had revoked the EUA for Chembio's DPP antibody test, reportedly citing performance concerns with the test's accuracy, a determination that its "benefits no longer outweigh its risks", and "a higher than expected rate of false results."

On this news, Chembio's stock price fell $6.04 per share, or 60.83%, to close at $3.89 per share on June 17, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 594634

NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors of The GEO Group, Inc. ("GEO Group" or the "Company") (NYSE:GEO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether GEO Group and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 17, 2020, The Intercept published an article entitled "GEO Group's Blundering Response to the Pandemic Helped Spread Coronavirus in Halfway Houses." The article reported details of a significant COVID-19 outbreak at the Grossman Center, a halfway house in Leavenworth, Kansas operated by GEO Group-which "was for weeks the hardest hit federal halfway house in the country" in terms of confirmed cases of COVID-19. Citing interviews with residents of the Grossman Center, The Intercept characterized GEO Group's response as "blundering" and reported, "that the virus spread not in spite of the facility's efforts to contain it, but because of it." According to the article, the Grossman Center continued to keep its residents in overcrowded conditions without enforcing personal protective measures even as COVID-19 diagnoses at the facility increased.

On this news, GEO Group's stock price fell $1.03 per share, or 7.8%, to close at $12.17 per share on June 17, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 594633

NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ:CODX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On May 14, 2020, The Salt Lake Tribune reported that TestUtah.com, which used tests developed by Co-Diagnostics, "declined to join other major Utah labs in a joint experiment to confirm one another's quality." The Salt Lake Tribune further reported that Co-Diagnostics' tests "have a higher ‘limit of detection'-that is, they require more of the virus to trigger a positive result-than most other coronavirus tests approved for sale in the U.S., according to an analysis by the life sciences publication BioCentury." Accordingly, Co-Diagnostics tests were likely to have a higher false negative reporting rate, meaning that potentially thousands of infected people were inaccurately told that they did not have the disease. The article also reported concerns related to TestNebraska.com and TestIowa.com, other testing services that also used Co-Diagnostics tests.

On this news, Co-Diagnostics' stock price fell $5.06 per share, or 22.86%, to close at $17.07 per share on May 15, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 594631

SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2020 / Hagens Berman urges investors in Enphase Energy, Inc. (NASDAQ:ENPH) who suffered losses in excess of $150,000 to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

Class Period: Feb. 26, 2019 – June 17, 2020
Lead Plaintiff Deadline: Aug. 17, 2020
Visit: www.hbsslaw.com/investor-fraud/ENPH
Contact An Attorney Now: ENPH@hbsslaw.com
844-916-0895

Enphase Energy (ENPH) Securities Fraud Class Action:

The complaint alleges that Enphase misrepresented and concealed that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and that (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Investors began to learn the truth, according to the complaint, on June 17, 2020, when research firm Prescience Point published a report concluding that "[a]t least $205.3m of ENPH's reported FY19 US revenue is fabricated, and a significant portion of its international revenue is fabricated as well." Prescience Point also noted since the start of June, possibly when insiders became aware of its investigation, Enphase insiders dumped $120.9 million in stock at inflated prices.

In response, the price of Enphase shares plummeted over 25% on June 17, 2020.

"We're focused on investors' losses and proving that Enphase misreported revenues and inflated margins," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Enphase and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Enphase should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ENPH@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 594622

LOS ANGELES, CA / ACCESSWIRE / June 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Akazoo S.A. ("Akazoo" or "the Company") (NASDAQ:SONG) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 11, 2019 and April 20, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before June 23, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Akazoo overstated important financial measures, including revenue, profits, and cash holdings. The Company overstated the amount of music it held distribution rights for by a significant degree. It also has a much smaller userbase than it purports to have. The Company does not operate in 25 companies despite its continuing claims to do so and has closed its headquarters and various other offices. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Akazoo, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594621

LOS ANGELES, CA / ACCESSWIRE / June 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc. ("Chembio" or "the Company") (NASDAQ:CEMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between April 1, 2020 and June 16, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Chembio's COVID-19 antibody test was among the first to be granted Emergency Use Authorization (EUA) by the FDA in April. The FDA revoked the Company's EUA on June 17, 2020, based on concerns of test accuracy. According to the FDA, the "benefits no longer outweigh its risks" and that "it is not reasonable to believe that the test may be effective" because it "generates a higher than expected rate of false results and higher than that reflected in the authorized labeling for the device." Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Chembio, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594611

LOS ANGELES, CA / ACCESSWIRE / June 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Baidu, Inc. ("Baidu" or "the Company") (NASDAQ:BIDU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 16, 2019 and April 7, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before June 22, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Baidu failed to maintain compliance with Chinese laws and regulations with its feed services. The Company was at a heightened risk of enforcement action by the Chinese government based on the noncompliance. This threat meant that the Company's revenues derived from online marketing were likely not to be sustainable. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about Baidu, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594620

LOS ANGELES, CA / ACCESSWIRE / June 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Wirecard AG ("Wirecard" or "the Company") (OTC PINK:WCAGY)(OTC PINK:WRCDF) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Wirecard announced on June 18, 2020, that about 1.9 billion euros ($2.1 billion) in cash has gone missing, shocking investors. The Company admitted that loans of up to 2 billion euros could be terminated based on additional delay in publishing its financial results, which have already been delayed four times. Auditor Ernst & Young could not confirm the location of the missing cash, saying evidence of "spurious balance confirmations" had been provided. According to Wirecard, the missing money accounts to about a quarter of the Company's balance sheet. Shares of Wirecard have traded down by about 70% since the announcement.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594613

LOS ANGELES, CA / ACCESSWIRE / June 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Endo International plc ("Endo" or "the Company") (NASDAQ:ENDP) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Endo is the subject of a press release from the New York Department of Financial Services ("DFS") published on June 10, 2020. According to the DFS, it "has filed charges and initiated administrative proceedings against Endo International plc and its subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., and Par Pharmaceutical Companies, Inc." The charged on based on an ongoing DFS investigation of companies that created and perpetuated the opioid crisis." According to the release, "The DFS' statement of charges alleges that, like other opioid Manufactures, Endo . . . knowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks"; "misrepresented the safety and efficacy of opioids, without legitimate scientific substantiation"; and "deployed a large sales force to target healthcare providers directly with these misrepresentations." Based on this news, shares of Endo fell sharply, harming investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594612